Drug Profile
Research programme: immuno-oncology targeted monoclonal antibody therapeutics - HiFiBio/Pierre Fabre
Latest Information Update: 28 Apr 2021
Price :
$50
*
At a glance
- Originator H-Immune; Pierre Fabre
- Developer HiFiBiO; Pierre Fabre
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer